GLP‑1 and muscle loss risk
Practical fitness reporting is flagging muscle loss as a common side effect of GLP‑1 medications, and trainers recommend resistance training plus adequate nutrition to preserve lean mass during weight loss. Those are straightforward steps you can add to a program if you or someone you advise is using these drugs. (fitandwell.com)
These drugs help people lose weight by making them feel full sooner and stay full longer, which means many patients eat less without white-knuckling every meal. In the 68-week STEP 1 trial, adults taking semaglutide lost an average of 14.9% of body weight versus 2.4% with placebo, alongside lifestyle changes. (nejm.org) When weight drops fast, the body usually does not pull only from fat stores. It also sheds lean mass, which is the bucket that includes muscle, organs, bone, and body water, like moving houses and losing furniture along with boxes of junk. (nature.com) That is why muscle keeps coming up in the GLP-1 conversation. A 2024 Nature Reviews Endocrinology comment said loss of skeletal muscle mass is emerging as a possible side effect of these potent weight-loss drugs and raised concern about sarcopenia, the age-linked loss of muscle and strength. (nature.com) In an exploratory body-composition analysis from STEP 1, semaglutide reduced total fat mass, but lean body mass also fell. The Obesity Medicine Association says about 40% of the body-weight reduction in that pivotal semaglutide trial came from lean mass, even though lean mass is not the same thing as muscle alone. (academic.oup.com) (obesitymedicine.org) The newer data are a little less alarming than the social-media version of this story. A January 2026 JAMA Network Open study of 3,066 patients found semaglutide and tirzepatide were linked to substantial fat-mass loss and modest fat-free-mass loss over 24 months, while the ratio of fat-free mass to fat mass still improved. (jamanetwork.com) But “modest” does not mean “ignore it,” because muscle does jobs fat cannot do. Skeletal muscle helps with strength, balance, glucose disposal, and day-to-day function like climbing stairs, standing up from a chair, and carrying groceries. (nature.com) The practical fix is not exotic. The Obesity Medicine Association says the best-supported steps so far are resistance training and adequate protein and micronutrient intake, although it also notes formal guidelines to prevent muscle loss on these drugs have not yet been developed. (obesitymedicine.org) Resistance training means giving muscle a reason to stay, the way a company keeps a factory open if orders are still coming in. The Centers for Disease Control and Prevention says adults should do muscle-strengthening activity at least 2 days a week, in addition to 150 minutes of moderate-intensity activity. (cdc.gov) Food matters because these drugs often blunt appetite enough that people accidentally under-eat for months. A 2025 International Journal of Obesity perspective argued there is still a nutrition-guidance gap for glucagon-like peptide-1 receptor agonist therapy and suggested lessons from bariatric surgery, where protein intake is treated as a priority during weight loss. (nature.com) The cleanest way to think about this is that the goal is not just a lower number on the scale. The goal is losing as much fat as possible while keeping as much strength and function as possible, which is why clinicians and trainers keep pairing these medications with weights, protein, and follow-up instead of treating the injection as a complete program. (jamanetwork.com) (obesitymedicine.org)
